They also further indicate that RUNX1 has the potential to be combined with chemotherapy drugs in the clinical treatment of ovarian cancer, thereby bringing better prognosis and quality of life to patients with ovarian cancer (Figure 3). The gene discussed is RUNX1; the disease is ovarian carcinoma.